주식/증권
📈 긍정적
Cytokinetics Gains 20.5% YTD: Buy, Sell or Hold the Stock?
요약
Myqorzo's early launch momentum and global expansion could boost Cytokinetics, while pipeline progress may widen its growth opportunity.